Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sitagliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 12/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 1.00 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 1.00 |
| ▸ | ACE | P12821 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | FAP | Q12884 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sitagliptin SCHEMBL31513245 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL29421658 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL174489 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL1289311 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL17783 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL19520418 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL30885792 | 0.99 | DPP4 (0.98) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL572135 | 0.99 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL1533793 | 0.99 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL18131636 | 0.98 | DPP4 (0.98) | DPP4DPP8DPP9DPP7ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12344874-B2 | Transaminase biocatalysts | CODEXIS, INC. (US) | 2025-07-01 | — | — | US | claimed |
| CN-119082225-A | Sitagliptin Process for the preparation of intermediates | 浙江赞源生物技术有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-112048485-B | Engineered transaminase polypeptide for preparing sitagliptin | 宁波酶赛生物工程有限公司 | 2022-09-27 | — | — | CN | claimed |
| CN-121586585-A | Compounds for up-regulating myotrophic related protein levels in muscle cells and methods of use thereof | 肽智科技私人有限公司 | 2026-02-27 | — | — | CN | disclosed |
| EP-4694979-A2 | COMPOUNDS FOR UPREGULATING UTROPHIN LEVELS IN MUSCLE CELLS AND METHOD OF APPLICATION THEREOF | Peptris Technologies Private Limited (IN) | 2026-02-18 | — | — | EP | disclosed |
| US-12545705-B2 | IBAT inhibitors for the treatment of liver diseases | ALBIREO AB (SE) | 2026-02-10 | — | — | US | disclosed |
| EP-4469459-B1 | PROCESS FOR PREPARING CRYSTALLINE SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE | ZAKL FARMACEUTYCZNE POLPHARMA S A (PL) | 2026-01-21 | — | — | EP | disclosed |
| EP-3781261-B1 | ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING DPP-4 INHIBITOR | SANOVEL ILAC SANAYI VE TICARET AS (TR) | 2025-11-26 | — | — | EP | disclosed |
| US-20250326789-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2025-10-23 | — | — | US | disclosed |
| WO-2025122076-A1 | FIXED-DOSE COMBINATION FORMULATIONS WITH LOW LEVEL OF IMPURITY PROFILE | SANTA FARMA ILAC SANAYII A.S. (TR) | 2025-06-12 | — | — | WO | disclosed |
| EP-4566593-A1 | A TABLET COMPRISING AN EXTENDED-RELEASE FORMULATION FOR METFORMIN AND IMMEDIATE RELEASE FORMULATION COMPRISING SITAGLIPTIN | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2025-06-11 | — | — | EP | disclosed |
| EP-3999070-A1 | AN EFFERVESCENT TABLET COMPOSITION OF SITAGLIPTIN | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2022-05-25 | — | — | EP | disclosed |
| CN-114516847-A | Preparation method of sitagliptin intermediate | 台州达辰药业有限公司 | 2022-05-20 | — | — | CN | disclosed |
| EP-3996704-A1 | COMBINATION THERAPY OF GPR119 AGONISTS AND DPP-4 INHIBITORS | MANKIND PHARMA LTD (IN) | 2022-05-18 | — | — | EP | disclosed |
| WO-2022074664-A1 | AN IMMEDIATE RELEASE COMPOSITION OF SITAGLIPTIN HYDROCHLORIDE | V-ENSURE PHARMA TECHNOLOGIES PRIVATE LIMITED (IN) | 2022-04-14 | — | — | WO | disclosed |
| CN-109896980-B | Biosynthesis method of sitagliptin intermediate | 浙江九洲药业股份有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-113430184-B | Transaminase and application thereof in preparation of sitagliptin | 台州酶易生物技术有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114206894-A | Prodrug platforms useful for the delivery of amines, amides and phenols | 上海长乘医药科技有限公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2022035400-A1 | A TABLET FORMULATION COMPRISING SITAGLIPTIN AND METFORMİN | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2022-02-17 | — | — | WO | disclosed |
| CN-113979896-A | Sitagliptin impurity I and preparation method thereof | 浙江永太手心医药科技有限公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326789-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | GPR119, SLC10A1, SLC10A2 | DPP4 580/4885DPP8 726/4885DPP9 502/4885 |
| US-12545705-B2 | IBAT inhibitors for the treatment of liver diseases | SLC10A2, SLC10A1, CLIC1 | DPP4 942/4885DPP8 418/4885DPP9 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.